John Johnson, DO
Allergy & Immunology · Yarmouth Port, MANPI 1043650641
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by GSK at 42.2% of the total. Reporting peaked in 2020 at $10,812 and has fallen 77.1% since, to $2,480 in 2025.
Across 546 payments — averaging $54.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12K
- AstraZeneca$9K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$937
- CSL Behring$594
- Takeda Pharmaceuticals U.S.A., Inc.$574
- plus $4K from 31 others
Across 13 payments — averaging $2855.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$37K
What the payments were for
- Speaking & faculty fees$16,25055%
- Food & beverage$13,24745%
- Education$1360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $12,496 |
| AstraZeneca | 135 | $9,166 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,383 |
| Sanofi | 30 | $937 |
| CSL Behring | 25 | $594 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $574 |
| Novartis | 35 | $565 |
| Amgen(2 entities) | 20 | $412 |
| Grifols USA, LLC | 19 | $409 |
| Genentech USA, Inc. | 21 | $384 |
| Boehringer Ingelheim | 13 | $313 |
| Alk-abello, Inc | 10 | $261 |
| Biocryst US Sales Co., LLC | 11 | $254 |
| Pharming Healthcare, Inc. | 10 | $208 |
| Pfizer | 8 | $197 |
| LEO Pharma Inc. | 8 | $182 |
| Kaleo, Inc. | 9 | $179 |
| Teva Pharmaceuticals USA, Inc. | 6 | $129 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $119 |
| Shire North American Group Inc | 6 | $110 |
| Mylan Specialty L.p. | 5 | $103 |
| Aimmune Therapeutics, Inc. | 5 | $97 |
| Optinose US, Inc. | 4 | $88 |
| AbbVie | 3 | $80 |
| Octapharma USA, Inc. | 1 | $69 |
| USWM, LLC | 2 | $43 |
| Biocryst Pharmaceuticals, Inc. | 2 | $40 |
| Ionis Pharmaceuticals, Inc. | 1 | $38 |
| Organon | 2 | $33 |
| X4 Pharmaceuticals, Inc. | 1 | $32 |
| Invivyd Inc | 1 | $31 |
| Verona Pharma, Inc. | 1 | $23 |
| GC Biopharma USA, Inc. | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Pulmonx Corporation | 1 | $17 |
| Viiv Healthcare Company | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,633 in reported general payments places this provider in the 80th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 51 | $189,370 |
| XolairOmalizumab | 66 | $183,443 |
| Dupixent SyringeDupilumab | 27 | $125,383 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $120,567 |
| Breo ElliptaFluticasone/Vilanterol | 183 | $84,097 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $49,593 |
| Arnuity ElliptaFluticasone Furoate | 100 | $25,975 |
| Spiriva RespimatTiotropium Bromide | 28 | $21,936 |
| Wixela InhubFluticasone Propion/Salmeterol | 101 | $11,384 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 41 | $10,998 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,034 |
| Fluticasone Propionate HfaFluticasone Propionate | 24 | $8,645 |
| Epinephrine | 49 | $8,031 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 231 | $6,999 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $6,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $12,496 | $235,064425 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $9,166 | $63,83698 claims |
| Boehringer IngelheimSpiriva Respimat | $313 | $21,93628 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $8 | $4,11611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Yarmouth Port
- Paul SklarewYarmouth Port$5K
- Wanda PhipatanakulBoston$679K
- Jonathan BayukNorthampton$420K
- Kathleen BuchheitBoston$224K
- Francisco BonillaLeominster$188K
- Aleena BanerjiBoston$133K
- Margo StevensonSturbridge$98K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Maria CastellsGardner$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.